595 related articles for article (PubMed ID: 27022139)
1. Role of mitochondrial dysfunction in cancer progression.
Hsu CC; Tseng LM; Lee HC
Exp Biol Med (Maywood); 2016 Jun; 241(12):1281-95. PubMed ID: 27022139
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis.
Sajnani K; Islam F; Smith RA; Gopalan V; Lam AK
Biochimie; 2017 Apr; 135():164-172. PubMed ID: 28219702
[TBL] [Abstract][Full Text] [Related]
3. Mitochondria in cancer: at the crossroads of life and death.
Fogg VC; Lanning NJ; Mackeigan JP
Chin J Cancer; 2011 Aug; 30(8):526-39. PubMed ID: 21801601
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of mitochondrial DNA in aging and cancer progression.
Lee HC; Chang CM; Chi CW
Ageing Res Rev; 2010 Nov; 9 Suppl 1():S47-58. PubMed ID: 20816876
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.
Desideri E; Vegliante R; Ciriolo MR
Cancer Lett; 2015 Jan; 356(2 Pt A):217-23. PubMed ID: 24614286
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial determinants of cancer health disparities.
Choudhury AR; Singh KK
Semin Cancer Biol; 2017 Dec; 47():125-146. PubMed ID: 28487205
[TBL] [Abstract][Full Text] [Related]
7. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Menendez JA; Alarcón T; Joven J
Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
[TBL] [Abstract][Full Text] [Related]
8. Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.
Ristic B; Bhutia YD; Ganapathy V
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):246-257. PubMed ID: 28512002
[TBL] [Abstract][Full Text] [Related]
9. Role of mitochondrial alterations in human cancer progression and cancer immunity.
Wang SF; Tseng LM; Lee HC
J Biomed Sci; 2023 Jul; 30(1):61. PubMed ID: 37525297
[TBL] [Abstract][Full Text] [Related]
10. Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression.
Lee HC; Huang KH; Yeh TS; Chi CW
World J Gastroenterol; 2014 Apr; 20(14):3950-9. PubMed ID: 24744584
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial alterations during carcinogenesis: a review of metabolic transformation and targets for anticancer treatments.
Wang X; Peralta S; Moraes CT
Adv Cancer Res; 2013; 119():127-60. PubMed ID: 23870511
[TBL] [Abstract][Full Text] [Related]
12. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer.
Guerra F; Guaragnella N; Arbini AA; Bucci C; Giannattasio S; Moro L
Front Oncol; 2017; 7():295. PubMed ID: 29250487
[TBL] [Abstract][Full Text] [Related]
14. Genetically modeled mice with mutations in mitochondrial metabolic enzymes for the study of cancer.
Piruat JI; Millán-Uclés A
Front Oncol; 2014; 4():200. PubMed ID: 25126540
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction in cancer chemoresistance.
Guaragnella N; Giannattasio S; Moro L
Biochem Pharmacol; 2014 Nov; 92(1):62-72. PubMed ID: 25107705
[TBL] [Abstract][Full Text] [Related]
16. Role of mitochondria in carcinogenesis.
Tokarz P; Blasiak J
Acta Biochim Pol; 2014; 61(4):671-8. PubMed ID: 25493442
[TBL] [Abstract][Full Text] [Related]
17. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
King A; Selak MA; Gottlieb E
Oncogene; 2006 Aug; 25(34):4675-82. PubMed ID: 16892081
[TBL] [Abstract][Full Text] [Related]
18. The Significance of Mitochondrial Dysfunction in Cancer.
Luo Y; Ma J; Lu W
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32764295
[TBL] [Abstract][Full Text] [Related]
19. Stress-related mitochondrial components and mitochondrial genome as targets of anticancer therapy.
Giannattasio S; Guaragnella N; Arbini AA; Moro L
Chem Biol Drug Des; 2013 Jan; 81(1):102-12. PubMed ID: 23253132
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial Tumor Suppressors-The Energetic Enemies of Tumor Progression.
Jakoube P; Cutano V; González-Morena JM; Keckesova Z
Cancer Res; 2021 Sep; 81(18):4652-4667. PubMed ID: 34183354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
